In vitro selection and molecular characterization of human immunodeficiency virus type 1 with reduced sensitivity to 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA)

Antiviral Research

Volumn 32, Issue 2, 1996, Pages 91-98

  Foli, Andrea ^a   Sogocio, Kristina M ^a   Anderson, Barry ^a   Kavlick, Mark ^a   Saville, M Wayne ^a   Wainberg, Mark A ^b   Gu, Zhengxian ^b   Cherrington, Julie M ^c   Mitsuya, Hiroaki ^a   Yarchoan, Robert ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c GILEAD SCIENCES   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Drug resistant virus; HIV 1; Reverse transcriptase mutations

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; MOLECULAR CLONING; MUTAGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030271097     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00985-X     Document Type: Article

References (37)

1. Balzarini, J., Naesens, L., Herdewijn, P., Rosenberg, I., Holy, A., Pauwels, R., Baba, M., Johns, D.G. and De Clercq, E. (1989) Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc. Natl. Acad. Sci. USA 86, 332-336.
2. Balzarini, J., Naesens, L. and De Clercq, E. (1990) Anti-retrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in vivo increases when it is less frequently administered. Int. J. Cancer 46, 337-340.
3. Balzarini, J., Naesens, L., Slachmuylders, J., Niphuis, H., Rosenberg, I., Holy, A., Schellekens, H. and De Clercq, E. (1991a) 9-(2-Phosphonylmethoxyethyl)adenine (PMEA) effectively inhibits retrovirus replication in vitro and simian immunodeficiency virus infection in rhesus monkeys. AIDS 5, 21-28.
4. Balzarini, J., Zhang, H., Herdewijn, P., Johns, D. and De Clercq, E. (1991b) Intracellular metabolism and mechanism of antiretrovirus action of 9-(2-phosphonylmethoxy)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. USA 88, 1499-1503.
5. Boucher, C.A., Tersmette, M., Lange, J.M.A., Kellam, P., de Goede, R.E.Y., Mulder, J.W., Darby, G., Goudsmit, J. and Larder, B.A. (1990) Zidovudine sensitivity of human immunodeficiency viruses from high-risk, symptom-free individuals during therapy. Lancet 2, 585-590.
6. Cherrington, J.M., Mulato, A.S., Fuller, M.D. and Chen, M.S. (1995) In vitro selection and characterization of HIV-1 viral isolates with reduced sensitivity to PMEA. HIV Drug Resistance 4th Int. Workshop, Sardinia, Italy, July 6-9, 1995, abstr. no. 12.
7. Collier, A.C., Coombs, R.W., Nienow, J., Paradise, M., Yang, H.H., Troxel, S., Boggs, J., Ebeling, D., Jaffe, H.S. and Corey, L. (1993) A phase I/II study of 9-(2-phosphonylmethoxyethyl)adenine (PMEA) in advanced HIV infection. 1st Natl. Conf. Human Retro viruses, Washington, DC, USA, Dec. 12-17, 1993, abstr. no. 158.
8. De Clercq, E., Holy, A., Rosenberg, I., Sakuma, T., Balzarini, J. and Maudgal, P. (1986) A novel selective broad-spectrum anti-DNA virus agent. Nature 323, 464-467.
9. Gao, Q., Gu, Z., Hiscott, J., Dionne, G. and Wainberg, M.A. (1993a) Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 37, 130-133.
10. Gao, W.-Y., Shirasaka, T., Johns, D.G., Broder, S. and Mitsuya, H. (1993b) Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J. Clin. Invest. 91, 2326-2333.
11. Gu, Z., Gao, Q., Li, X., Parniak, M.A. and Wainberg, M.A. (1992) Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine. J. Virol. 66, 7128-7135.
12. Gu, Z., Gao, Q., Fang, H., Salomon, H., Parniak, M.A., Goldberg, F., Cameron, J. and Wainberg, M.A. (1994) Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2′,3′-dideoxycytidine and 2′,3′-dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 38, 275-281.
13. Gu, Z., Salomon, H., Cherrington, J.M., Mulato, A.S., Chen, M.S., Yarchoan, R., Foli, A., Sogocio, K.M. and Wainberg, M.A. (1995) K65R mutation of HIV-1 reverse transcriptase encodes cross-resistance to 9-(2-phosphonylmethoxyethyl)adenine. Antimicrob. Agents Chemother. 39, 1888-1891.
14. Harada, S., Koyanagi, Y. and Yamamoto, N. (1985) Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 229, 563-566.
15. Japour, A.J., Mayers, D.L., Johnson, V.A., Kuritzkes, D.R., Beckett, L.A., Arduino, J.M., Lane, J., Black, R.J., Reichelderfer, P.S., D'Aquila, R.T., Crumpacker, C.S., the RV-43 Study Group and the AIDS Clinical Trials Group Virology Committee Resistance Working Group (1993) Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob. Agents Chemother. 37, 1095-1101.
16. Johnson, V.A. and Byington, R.E. (1990) In: A. Aldovini and B.D. Walker (Eds), Techniques in HIV Research, pp. 71-76. Stockton Press, New York.
17. Kavlick, M.F., Shirasaka, T., Kojima, E., Pluda, J.M., Hui Jr., F., Yarchoan, R. and Mitsuya, H. (1995) Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2′,3′-dideoxy-3′-thiacytidine. Antiviral Res. 133-146.
18. Larder, B.A. and Kemp, S.D. (1989) Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 246, 1155-1158.
19. Lush, R.M., Nguyen, B.-Y., Cundy, K.C., Bauza, S., Sogocio, K., Syevens, J., Piscitelli, S.C., Venzon, D.J., Yarchoan, R. and Figg, W.D. (1996) The pharmacokinetics of (S)-9-[2-(phosphonylmethoxy)ethyl]adenine (PMEA) and ziduvudine (AZT) when administered in combination. J. Appl. Ther. (in press).
20. Myers, G., Korber, B., Berzofsky, J.A., Smith, R.F. and Pavlakis, G.N. (1992) Human Retroviruses and AIDS 1992. Los Alamos National Laboratory, Los Alamos.
21. Pauwels, R., Balzarini, J., Schols, D., Baba, M., Desmyter, J., Rosenberg, I., Holy, A. and De Clercq, E. (1988) Phosphonylmethoxyethyl purine derivatives: a new class of anti-human immunodeficiency virus agents. Antimicrob. Agents Chemother. 32, 1025-1030.
22. Perno, C.-F., Cooney, D.A., Gao, W.-Y., Hao, Z., Johns, D.G., Foli, A., Hartman, N.R., Calio, R., Broder, S., and Yarchoan, R. (1992) Effects of bone marrow stimulatory cytokines on human immunodeficiency virus replication and the antiviral activity of dideoxynucleosides in cultures of monocyte/macrophages. Blood 80, 995-1003.
23. Richman, D., Shih, C.-K., Lowy, I., Rose, J., Prodanovich, P., Goff, S. and Griffin, J. (1991) Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA 88, 11241-11245.
24. Richman, D.D. (1993) Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob. Agents Chemother. 37, 1207-1213.
25. Schinazi, R.F., Lloyd Jr., R.M., Nguyen, M.-H., Cannon, D.L., McMillan, A., Irksoy, N., Chu, C.K., Liotta, D.C., Bazmi, H.Z. and Mellors, J.W. (1993) Characterization of human immunodeficiency viruses resistant to oxathiolanecytosine nucleosides. Antimicrob. Agents Chemother. 37, 875-881.
26. Schinazi, R., Larder, B. and Mellors, J. (1994) Mutations in HIV-1 reverse transcriptase and protease associated with drug resistance. Int. Antiviral News 2, 72-75.
27. Schuurman, R., Nijhuis, M., van Leeuwen, R., Schipper, P., de Jong, D., Collis, P., Danner, S.A., Mulder, J., Loveday, C., Christopherson, C., Kwok, S., Sninsky, J. and Boucher, C.A.B. (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171, 1441-1449.
28. Shirasaka, T., Yarchoan, R., O'Brien, M.C., Husson, R.N., Anderson, B.D., Kojima, E., Broder, S. and Mitsuya, H. (1993) Changes in drug-sensitivity of human immunodeficiency virus type I during therapy with azidothymidine, dideoxycytidine, or dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA 90, 562-566.
29. Smith, M.S., Brian, E.L., De Clercq, E. and Pagano, J. (1989) Susceptibility of human immunodeficiency virus type 1 replication in vitro to acyclic analogs and synergy of the analogs with 3′-azido-3′-deoxythymidine. Antimicrob. Agents Chemother. 33, 1482-1486.
30. Starrett, S.E., Tortolani, D.R., Hitchcock, M.J.M., Martin, J.C. and Mansuri, M.M. (1992) Synthesis and in vitro evaluation of a phosphonate prodrug: bis(pivaloyloxymethyl) 9-(2-phosphonylmethoxyethyl)adenine. Antiviral Res. 19, 267-273.
31. Tisdale, M., Kemp, S.D., Parry, N.R., and Larder, B.A. (1993) Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc. Natl. Acad. Sci. USA 90, 5653-5656.
32. Tsai, C.-C., Follis, K.E., Sabo, A., Grant, R.F., Bartz, C., Nolte, R.E., Benveniste, R.E. and Bischofberger, N. (1994) Preexposure prophylaxis with 9-(2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J. Infect. Dis. 169, 260-266.
33. Tsai, C.-C., Follis, K.E., Sabo, A., Beck, T.W., Grant, R.F., Bischofberger, N., Benveniste, R.E. and Black, R. (1995) Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270, 1197-1199.
34. Vasudevachari, M.B., Battista, C., Lane, H.C., and Salzman, N.P. (1993) Inhibition of HIV-1 by 9-(2-phosphonylmethoxyethyl)adenine (PMEA) and in vitro selection of variants of HIV-1 resistant to PMEA. ASM Conf. Molecular Diagnostics and Therapeutics, Jackson Lake, Moran, WY, USA, 1993.
35. Wainberg, M.A., Salomon, H., Gu, Z., Montaner, J.S.G., Cooley, T.P., McCaffrey, R., Ruedy, J., Hilary, M.H., Cammack, N., Cameron, J. and Nicholson, W. (1995) Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS 9, 351-357.
36. Walker, R.E., Vogel, S.E., Jaffe, H.S., Polis, M.A., Kovacs, J.A., Falloon, J., Davey, R.T., Ebeling, D., Cundy, K., Paar, D., Markowitz, N., Masur, H. and Lane, H.C. (1993) A phase I/II study of PMEA in HIV infected patients. 1st Natl. Conf. Human Retroviruses, Washington, DC, USA, Dec. 12-17, 1993, abstr. no. 148.
37. Zhang, D., Caliendo, A.M., Eron, J.J., DeVore, K.M., Kaplan, J.C., Hirsch, M.S. and D'Aquila, R.T. (1994) Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38, 282-287.